Sol-Gel Technologies Ltd. (NasdaqCM: SLGL)
Health Care · Pharmaceuticals · IL
$72.70
+1.30% today · +84.1% 1Y
Sol-Gel Technologies Ltd. (NasdaqCM: SLGL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $234.97M and employs 28 people.
Over the last twelve months the share price has gained 84.1%, trading between 28.81 and 97.97.
Tweenvest scores Sol-Gel Technologies Ltd. across four factors: quality 40/100, value 56/100, growth 100/100. Its strongest factor is growth.
SLGL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $234.97M
- Revenue (TTM)
- $1.79M
- P/E
- —
- EPS
- -5.59
- Dividend yield
- —
- Beta (5Y)
- 1.15
- 52-week high
- $97.97
- 52-week low
- $28.81
- Avg volume (3M)
- —
- Shares outstanding
- 3.27M
- Employees
- 28
- Next earnings
- —
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
- ISIN
- IL0011417206
- Founded
- 1997
- Listed since
- Feb 1, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Auxly Cannabis Group Inc.TSX: XLY | $241.66M | CA$3.34 | +2.45% |
| Cresco Labs Inc.CNSX: CL | $239.19M | CA$0.92 | -3.16% |
| SIGA Technologies, Inc.NasdaqGM: SIGA | $235.67M | $3.17 | -3.51% |
| Daito Pharmaceutical Co.,Ltd.TSE: 4577 | $235.23M | ¥1,318.00 | +0.69% |
| High Tide Inc.TSXV: HITI | $234.28M | CA$3.75 | +1.90% |
| Sakar Healthcare LimitedNSEI: SAKAR | $232.54M | Rs1,011.50 | -5.91% |
| Savior Lifetec CorporationTPEX: 4167 | $228.12M | NT$22.00 | +12.53% |
| Syncom Formulations (India) LimitedBSE: 524470 | $225.92M | Rs23.26 | -2.96% |
Figures last refreshed Oct 11, 2026.